These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30876619)

  • 1. Antibiotic Dosing in Chronic Kidney Disease and End-Stage Renal Disease: A Focus on Contemporary Challenges.
    Vilay AM
    Adv Chronic Kidney Dis; 2019 Jan; 26(1):61-71. PubMed ID: 30876619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic dosing in patients with renal insufficiency or receiving dialysis.
    Cunha BA; Friedman PE
    Heart Lung; 1988 Nov; 17(6 Pt 1):612-6. PubMed ID: 3056882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inadequate antibiotic dosing in patients receiving sustained low efficiency dialysis.
    Keough LA; Krauss A; Hudson JQ
    Int J Clin Pharm; 2018 Oct; 40(5):1250-1256. PubMed ID: 30051232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Measurements of vancomycin concentrations in the blood - a method of personalization the antibiotic therapy in patients with chronic kidney disease].
    Pondel J; Krajewski P; Królikowska N; Tobiasz A; Augustyniak-Bartosik H; Hurkacz M
    Pol Merkur Lekarski; 2017 Apr; 42(250):145-150. PubMed ID: 28530212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis.
    Jaffe G; Meyers BR; Hirschman SZ
    Antimicrob Agents Chemother; 1974 Jun; 5(6):611-6. PubMed ID: 15825414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of antibacterial agents in renal failure.
    Gilbert B; Robbins P; Livornese LL
    Infect Dis Clin North Am; 2009 Dec; 23(4):899-924, viii. PubMed ID: 19909890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?
    Jamal JA; Mueller BA; Choi GY; Lipman J; Roberts JA
    Diagn Microbiol Infect Dis; 2015 May; 82(1):92-103. PubMed ID: 25698632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin dosing and monitoring for patients with end-stage renal disease receiving intermittent hemodialysis.
    Crew P; Heintz SJ; Heintz BH
    Am J Health Syst Pharm; 2015 Nov; 72(21):1856-64. PubMed ID: 26490819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing of Aminoglycosides in Chronic Kidney Disease and End-Stage Renal Disease Patients Treated with Intermittent Hemodialysis.
    Halouzková BA; Hartinger JM; Krátký V; Tesař V; Slanař O
    Kidney Blood Press Res; 2022; 47(7):448-458. PubMed ID: 35443243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate?
    O'Shea S; Duffull S; Johnson DW
    Semin Dial; 2009; 22(3):225-30. PubMed ID: 19386073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic dosing adjustments in hospitalized patients with chronic kidney disease: a retrospective chart review.
    Chahine B
    Int Urol Nephrol; 2022 Jan; 54(1):157-163. PubMed ID: 33738646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Automated peritoneal dialysis: new implications for pharmacists.
    Brophy DF; Mueller BA
    Ann Pharmacother; 1997 Jun; 31(6):756-64. PubMed ID: 9184718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic dosing in slow extended daily dialysis.
    Mushatt DM; Mihm LB; Dreisbach AW; Simon EE
    Clin Infect Dis; 2009 Aug; 49(3):433-7. PubMed ID: 19580416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin dosing in patients on intermittent hemodialysis.
    Vandecasteele SJ; De Vriese AS
    Semin Dial; 2011; 24(1):50-5. PubMed ID: 21338394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model.
    Zhuang L; He Y; Xia H; Liu Y; Sy SK; Derendorf H
    J Antimicrob Chemother; 2016 Apr; 71(4):1012-21. PubMed ID: 26702923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-finding study of rivaroxaban in hemodialysis patients.
    De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
    Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of antibacterial agents in renal failure.
    Livornese LL; Slavin D; Gilbert B; Robbins P; Santoro J
    Infect Dis Clin North Am; 2004 Sep; 18(3):551-79, viii-ix. PubMed ID: 15308276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
    Abe M; Okada K; Soma M
    Curr Drug Metab; 2011 Jan; 12(1):57-69. PubMed ID: 21303332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibiotic therapy in kidney diseases with reduced kidney function].
    Briedigkeit H; Precht K
    Z Arztl Fortbild (Jena); 1983; 77(3):95-9. PubMed ID: 6344453
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.